<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03398811</url>
  </required_header>
  <id_info>
    <org_study_id>POCU</org_study_id>
    <nct_id>NCT03398811</nct_id>
  </id_info>
  <brief_title>Abnormal Uterine Bleeding and Progestin-only Contraceptives</brief_title>
  <official_title>Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of progestin-only methods of contraception has been increased obviously and&#xD;
      progressively over the world in the last few years. Progestin-only contraception is an option&#xD;
      for women in whom an estrogen-containing contraceptive is either contraindicated or causes&#xD;
      additional health concerns.&#xD;
&#xD;
      Progestogen-only pills are contraceptive pills that contain only synthetic progestogens&#xD;
      (progestins) and do not contain estrogen . The progestin-only pill is recommended over&#xD;
      regular birth control pills for women who are breastfeeding because the mini-pill does not&#xD;
      affect milk production.&#xD;
&#xD;
      The most common progestin-only method used is the injectable depot medroxy-progesterone&#xD;
      acetate which had been approved by Food and Drug Administration since 1992 . depot&#xD;
      medroxy-progesterone acetate provides reliable, private, long-acting (three months) and&#xD;
      reversible contraception. Users of depot medroxy-progesterone acetate don't need daily taking&#xD;
      as well as it doesn't affect the intercourse by any mean.&#xD;
&#xD;
      The etonogestrel implant (Implanon) is a single-rod progestin contraceptive method placed&#xD;
      subdermally in the inner aspect of upper non dependant arm for three years. Much evidence&#xD;
      supports the safety, efficacy, reversibility and acceptability of this contraceptive method.&#xD;
&#xD;
      A common reason women choose to discontinue progestin-only contraception is dissatisfaction&#xD;
      with its effects on uterine bleeding which occurs in a significant number of users.&#xD;
      Information revealed from many clinical trials shows that abnormal uterine bleeding with&#xD;
      progestin-only contraception ranging from 10 to 25 % at first year of use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">November 1, 2020</completion_date>
  <primary_completion_date type="Actual">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of women developed vaginal bleeding</measure>
    <time_frame>12 month</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">390</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Group I &quot;the depot medroxy-progesterone acetate group&quot;</arm_group_label>
    <description>where they will use Depot Medroxyprogesterone Acetate 150 mg injection every 3 month,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II &quot;Implanon group&quot;</arm_group_label>
    <description>where they will have Implanon (etonogestrel implant) 68 mg implant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group III (cerazette group)</arm_group_label>
    <description>where they are using Cerazette pills (desogestrel 75 µg l) one pill every day for 28 days without pill-free interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Depot medroxy-progesterone acetate</intervention_name>
    <description>Injection every 3 months</description>
    <arm_group_label>Group I &quot;the depot medroxy-progesterone acetate group&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel</intervention_name>
    <description>68 mg implant</description>
    <arm_group_label>Group II &quot;Implanon group&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel 75 µg</intervention_name>
    <description>one pill every day for 28 days without pill-free interval.</description>
    <arm_group_label>group III (cerazette group)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        women who requested DMPA, etonogestrel subdermal implant or POPs for pregnancy prevention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women aged between 18-40 years.&#xD;
&#xD;
          2. Women with more than 12 month postpartum.&#xD;
&#xD;
          3. Women who had normal menstrual pattern (cycle from 21 - 35 days with a same cycle&#xD;
             length variation of no more than 5 days, bleeding days from 2-7 days and number of&#xD;
             sanitary pads not more than 3 pads without blood clots or flooding of blood).&#xD;
&#xD;
          4. Women wanted to use DMPA, etonogestrel subdermal implant or POPs only for pregnancy&#xD;
             prevention for at least 1 year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women on any anticoagulant therapy.&#xD;
&#xD;
          2. Women who had a history of uterine, cervical or ovarian pathology.&#xD;
&#xD;
          3. Women who had uterine bleeding disturbance (including amenorrhea) before recruitment.&#xD;
&#xD;
          4. Women received DMPA injection within the previous 9 months except they had three&#xD;
             spontaneous regular menstrual cycles.&#xD;
&#xD;
          5. Severely anemic women (hemoglobin &lt; 8gm/dl).&#xD;
&#xD;
          6. Women with any contraindications for POCs following the WHO eligibility (Altshuler AL&#xD;
             et al., 2015).&#xD;
&#xD;
          7. Women refused to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 7, 2018</study_first_submitted>
  <study_first_submitted_qc>January 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Etonogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

